Astellas Institute for Renerative Medicine (ARIM)
The Astellas Institute for Regenerative Medicine (AIRM) was established in May 2016 following Astellas’ acquisition of Ocata Therapeutics. Headquartered in Marlborough, Mass., and supported by a research team in Tsukuba, Japan, AIRM is an indirect, wholly-owned subsidiary of Astellas and serves as the Company’s global hub for regenerative medicine in therapeutic areas that have few or no available treatment options, as well as all cell and non-cell line therapy research in ophthalmology. Together with AIRM, Astellas is focused on early discovery of cell therapy products for a variety of diseases through a combination of in-house research and external collaborations, using existing technologies and the creation of proprietary technologies.
